Bullish indicating open at $55-$60, IPO prices at $37
On Monday, TG Therapeutics (NASDAQ:TGTX) shares surged following a reiteration of an Overweight rating by Cantor Fitzgerald. The biopharmaceutical company, which specializes in developing treatments for B-cell mediated diseases, saw its stock rise by more than 18%, contrasting with a 1% decline in the XBI biotech index. The stock, currently trading at $35.43, is near its 52-week high of $36.84 and has delivered an impressive 67.5% return over the past year. According to InvestingPro analysis, the stock appears to be trading near its Fair Value.
The positive momentum comes on the heels of TG Therapeutics’ fourth-quarter earnings call, where management highlighted encouraging trends for Briumvi, their anti-CD20 drug for multiple sclerosis. January and February witnessed the highest number of new patient enrollments in the Briumvi hub since the drug’s launch, suggesting strong market uptake. The company’s impressive 88.3% gross profit margin and 39.5% revenue growth in the last twelve months reflect strong commercial execution. InvestingPro data reveals 11 additional key insights about TGTX’s performance and potential.
Cantor Fitzgerald’s analysis points to potential upside for Briumvi’s 2025 revenue guidance, which currently stands at $525 million in the U.S. market. The firm’s confidence is bolstered by recent management commentary indicating that these early trends could lead to higher-than-expected sales figures. Analyst consensus is strongly bullish, with price targets ranging from $10 to $55 per share, suggesting significant potential upside.
In discussions with TG Therapeutics’ management following the earnings call, Cantor Fitzgerald gathered further insights. The firm’s analysts are optimistic about the company’s prospects, citing TG Therapeutics as a "highly de-risked commercial story." They anticipate another beat and raise scenario for Briumvi’s 2025 revenue, driven by strong cash flow generation and the added potential from a subcutaneous formulation of Briumvi that could offer high operating leverage. InvestingPro’s Financial Health Score rates TGTX as "GREAT," with particularly strong scores in growth and price momentum. For deeper insights, access the comprehensive Pro Research Report available for TGTX and 1,400+ other US stocks.
TG Therapeutics’ positive trajectory is underpinned by these recent developments, which suggest a robust commercial performance and promising financial outlook for the upcoming years. The company’s focus on delivering innovative treatments for patients with B-cell mediated diseases continues to gain traction, as evidenced by the strong market response to Briumvi.
In other recent news, TG Therapeutics announced impressive financial results for the fourth quarter of 2024, reporting earnings per share (EPS) of $0.15, which exceeded analyst expectations of $0.08. The company’s revenue for the quarter reached $108.19 million, surpassing the anticipated $97.66 million. This marked a significant year-over-year growth, driven by strong U.S. net product sales of BRIUMVI, which totaled $103.6 million for the quarter and $310 million for the full year. The company has set a revenue guidance of $525 million for 2025, indicating continued growth momentum.
Additionally, TG Therapeutics has expanded BRIUMVI’s patent protection through 2042 and launched the product in Europe through a partnership with Neuraxpharm. The company is also advancing its development pipeline with new clinical trials and a global license agreement for a CAR T therapy program. Analyst firms have noted the company’s strong financial position, with $311 million in cash and equivalents as of the end of 2024, suggesting it is well-capitalized to pursue future growth opportunities. As part of its strategic initiatives, TG Therapeutics plans to explore new therapeutic areas, including myasthenia gravis, and enhance its offerings with subcutaneous formulations of BRIUMVI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.